Cargando…

Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α

Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase 2/3 trial were randomized 1:1 in an open label study to receive Nap+IFN-α or IFN-α. In this study, we analyzed the UK patients for their immunological response in relation...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkord, Eyad, Burt, Deborah J., Sundstedt, Anette, Nordle, Örjan, Hedlund, Gunnar, Hawkins, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414201/
https://www.ncbi.nlm.nih.gov/pubmed/25669986

Ejemplares similares